Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Acorda Therapeutics Inc

ACOR
Current price
0.44 USD -0.22 USD (-33.43%)
Last closed 0.38 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 821 028 USD
Yield for 12 month -9.09 %
1Y
3Y
5Y
10Y
15Y
ACOR
21.11.2021 - 28.11.2021

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Address: 2 Blue Hill Plaza, Pearl River, NY, United States, 10965

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10 USD

P/E ratio

Dividend Yield

Current Year

+117 633 000 USD

Last Year

+118 566 000 USD

Current Quarter

+37 985 000 USD

Last Quarter

+37 985 000 USD

Current Year

+71 586 000 USD

Last Year

+88 234 000 USD

Current Quarter

+24 696 000 USD

Last Quarter

+32 387 000 USD

Key Figures ACOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 8 402 000 USD
Operating Margin TTM 3.9 %
PE Ratio
Return On Assets TTM -5.77 %
PEG Ratio 0.51
Return On Equity TTM -23.68 %
Wall Street Target Price 10 USD
Revenue TTM 117 633 000 USD
Book Value -127.17 USD
Revenue Per Share TTM 94.71 USD
Dividend Share
Quarterly Revenue Growth YOY 20.7 %
Dividend Yield
Gross Profit TTM 82 430 000 USD
Earnings Share -203.57 USD
Diluted Eps TTM -203.57 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 587.3 %
Profit Margin -214.95 %

Dividend Analytics ACOR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ACOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 05.06.2023
Dividend Date 04.01.2021

Stock Valuation ACOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.3726
Price Sales TTM 0.007
Enterprise Value EBITDA -0.6935
Price Book MRQ 0.0527

Financials ACOR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ACOR

For 52 weeks

0.61 USD 24.2 USD
50 Day MA 11.41 USD
Shares Short Prior Month 9 465
200 Day MA 13.08 USD
Short Ratio 1.84
Shares Short 8 102
Short Percent 0.66 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics